How will the reorientation away from basic R&D impact resource deployment, particularly for in-licensing and asset acquisition?

R&D remains pivotally important, with continued investment in products like TEMBEXA, Ebanga, and raxibacumab, including MOSA trials for TEMBEXA in mpox. The reorientation aims to consolidate R&D and external business development under one leader to make faster, better decisions and improve capital allocation for future pipeline opportunities, driving better return on investment. “We think, however, by putting the decisions into one group where we bring the external business development and the internal R&D projects together into one decision-maker, we will have an ability to make faster decisions, better allocation of capital to the future pipeline opportunities, and that's where we think we'll get better return on investment for our shareholders going forward.”

Are there emergent trends in MCM contract procurement demands outside the US, given the increasingly dangerous global environment?

Yes, the company is seeing increased interest from governments globally. They highlighted concerns from AI CEO leadership about AI's potential misuse by bad actors to create new pathogens. Emergent intends to collaborate with AI leaders to help governments prepare for such bioterrorism threats, leveraging its experience in medical countermeasures preparedness. “Some of you may have seen recent articles back going back into June, where some of the AI CEO leadership are specifically writing letters of concern that AI could be utilized by bad actors to create new pathogens that could be very, very chaotic and cause additional problems. We intend, as we put out a release today to collaborate with the AI leaderships to make sure that we are going to be front and center there on helping governments around the world to prepare for the potential activities that could happen through AI that could expedite bad actors creating pathogens that are problematic.”

What is included in 'other revenue' and is its sustainability?

The biggest driver in 'other revenue' is the botulism anti-toxin (BAT) product, which saw a significant delivery in the third quarter that contributed to the year-over-year increase. “On the other revenue, the biggest driver there is our BAT product, botulism anti-toxin, and we had a significant delivery that occurred in the third quarter that really drove that year-over-year increase.”

EBS

Emergent BioSolutions (EBS) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Emergent BioSolutions Q2 FY26 — Strong MCM Performance Offsets Naloxone Headwinds

Emergent BioSolutions delivered strong Q2 FY26 results, exceeding revenue and adjusted EBITDA expectations, primarily driven by accelerated Medical Countermeasures (MCM) deliveries and contract awards. However, the company faces significant headwinds in its naloxone business due to increased competition and pricing pressure, leading to a downward revision of full-year revenue and profitability guidance. Management is implementing restructuring actions to improve cost structure and is reorienting R&D and business development to focus on high-return opportunities and address evolving public health threats.

Highlights

Q2 revenue of $234 million significantly exceeded the high end of prior guidance ($185 million)
Q2 adjusted EBITDA of $97 million, representing a 41% margin, up from 23% in Q2 2025
MCM revenue was $168 million in Q2, the highest second quarter revenue since 2020, driven by accelerated deliveries and contract awards
Secured over 10 contract awards year-to-date, including a $52.7 million modification for ACAM2000 and $64.5 million for botulism anti-toxin
Ended Q2 with $140 million of cash and $190 million of total liquidity, with an additional $145 million collected in July from accounts receivable

Concerns

Full-year 2026 revenue guidance revised down to $645 million-$675 million from $720 million-$760 million due to lower commercial revenue
Naloxone market experiencing increased competitive intensity, new entrants, and aggressive pricing pressures
Recorded a noncash impairment charge of approximately $191 million related to the NARCAN asset group due to updated market assessment
Adjusted EBITDA guidance revised down to $130 million-$150 million from $155 million-$175 million
GAAP net loss guidance widened to negative $245 million to negative $225 million, reflecting the impairment and restructuring costs

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Total Revenue	$645 million to $675 million high materiality	FY26	High
Full-year 2026 GAAP Net Loss	negative $245 million to negative $225 million high materiality	FY26	High
Full-year 2026 Adjusted Net Income	$10 million to $30 million high materiality	FY26	High
Full-year 2026 Adjusted EBITDA	$130 million to $150 million high materiality	FY26	High
Full-year 2026 Adjusted Gross Margin	42% to 44% medium materiality	FY26	High
Q3 2026 Total Revenue	$110 million to $130 million medium materiality	Q3 · FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Medical Countermeasures (MCM) Highest second quarter revenue since 2020, driven by accelerated deliveries and contract activity related to ACAM and BAT. Strong execution with U.S. and international government customers. International sales: 20% of total first half 2026 MCM revenues	$168 million	—	—	—
Commercial (Naloxone) Reflects NARCAN's market leadership position, but year-over-year performance was affected by new competitive pressure and continued pricing and volume dynamics. Lower overall commercial revenue is expected for the balance of the year. Market share: >50% of the naloxone market	—	—	—	—

Deals & partnerships

AI leaders and partners Collaboration to address bioterrorism risks and improve biodefense preparedness

Seeking to collaborate with AI leaders and partners to address the potential risk of bioterrorism and improve biodefense response preparedness, especially concerning AI's potential misuse to create new pathogens.

Risks & headwinds

Increased competitive pressure in naloxone market Near- to medium-term

Two new nasal naloxone entrants, including a new 4mg OTC approval on June 16, 2026, and a 10mg prescription agent launching in August 2026. Aggressive pricing across the naloxone segment.

Mitigation:Implementing restructuring actions to improve cost structure, focusing on NARCAN brand recognition, and introducing new innovations like carrying cases and multipacks.

Lower commercial revenue outlook H2 FY26

Full-year 2026 revenue guidance revised down by $75 million at midpoint (from $740M to $660M).

Mitigation:Cost savings initiatives and continued operating expense discipline partially offset the impact on adjusted EBITDA.

Potential misuse of AI for bioterrorism Ongoing

AI could be utilized by bad actors to create new pathogens that could be very, very chaotic and cause additional problems.

Mitigation:Seeking to collaborate with AI leaders and partners to be front and center in helping governments prepare for potential activities.

Ebola virus on the rise Ongoing

Ebola virus is on the rise in Africa.

Mitigation:Initiating a pan-Ebola therapeutic program.

What to watch in Q3 FY26

NARCAN sales erosion/stabilization

next quarter

Current Under pressure from new entrants and pricing

Target Stabilization of market share and pricing, or impact of new product configurations

Why it matters

The naloxone market dynamics are a key driver of the revised full-year guidance and the noncash impairment charge, impacting commercial revenue and overall profitability.

As market dynamics change, we need to proactively get ahead of these issues.

Find out whether EBS delivers this. Inve re-checks your case every morning.

Q&A highlights

What initiatives will slow NARCAN sales erosion and leverage brand recognition against next-gen fentanyl analogs?

Management is focusing on the strong NARCAN brand name, introducing new innovations like carrying cases and multipacks for high-volume users, and wall kits. They acknowledge competitive pricing pressures from new entrants but believe NARCAN will remain the 'gold standard' and aim to maintain market leadership.

“We're looking at, obviously, number one, the brand NARCAN itself is important. We have that brand name when you are looking at the opportunities that face the marketplace, having the brand name NARCAN is very important and we've had a chance to talk to consumers about that. They obviously recognize the importance of the NARCAN brand name.”

asked by Raghuram Selvaraju · answered by Joseph Papa

2 min read 6 chapters

Detailed narrative

Multiyear Transformation and Strategic Reorientation

Emergent is executing a multiyear transformation plan focused on improving operating performance, advancing strategic transformation for long-term growth and profitability, identifying growth opportunities, and strengthening the balance sheet. The company is unifying R&D and business development into a single 'growth organization' to enable faster, more informed portfolio decisions and better capital allocation, aiming for improved return on investment for shareholders.

Naloxone Market Dynamics and Competitive Pressure

The naloxone market, particularly for NARCAN, is experiencing significant changes due to the entry of two new nasal naloxone products, including a new 4mg OTC approval and a 10mg prescription agent. This has led to increased competitive intensity and aggressive pricing pressures.

While Emergent maintains market leadership with over 50% share, the company anticipates continued price erosion and has adjusted its commercial revenue outlook accordingly, despite ongoing efforts to innovate with new product configurations like carrying cases and multipacks.

Restructuring Actions and Cost Savings

To align resources with current business realities and prepare for 2027 and beyond, Emergent is implementing several restructuring actions. These include a reduction of approximately 90 positions, closure of two wet laboratories in Maryland, sale of an unutilized office building for $6.4 million, and exiting a central warehouse lease.

These efforts are expected to yield annualized savings of approximately $40 million, with the full run rate realized in 2027.

Strong Q2 Performance and MCM Business Strength

Emergent delivered strong second-quarter results, with revenue of $234 million significantly exceeding guidance and adjusted EBITDA of $97 million (41% margin). This performance was primarily driven by the Medical Countermeasures (MCM) segment, which recorded $168 million in Q2 revenue, the highest since 2020.

The company secured multiple U.S. government contract awards, including $52.7 million for ACAM2000 and $64.5 million for botulism anti-toxin, and saw international MCM sales represent 20% of total first-half MCM revenues.

Capital Allocation and Financial Flexibility

The company ended Q2 with $140 million in cash and $190 million in total liquidity, with an additional $145 million in accounts receivable collected in July. Gross debt was reduced to $590 million, and net leverage remained stable at 1.9x.

Emergent completed a term loan refinancing, extending maturities to 2031 and reducing interest rates. A new $75 million debt repurchase program for senior unsecured notes was authorized, and the company repurchased $9 million in shares during Q2, with $37.5 million remaining under the share repurchase program.

Addressing Biodefense and Public Health Threats

Emergent continues to focus on its mission to protect and save lives, supporting governments with critical products and capabilities. The company is initiating a pan-Ebola therapeutic program and advanced regulatory activities for ACAM2000 (Saudi FDA approval, Singapore HSA approval for mpox indication).

Emergent is also seeking to collaborate with AI leaders to address the potential risk of bioterrorism and improve biodefense preparedness, responding to concerns about AI's potential misuse in creating new pathogens.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.